<DOC>
	<DOCNO>NCT01020565</DOCNO>
	<brief_summary>The objective study demonstrate entecavir antiviral activity undetectable Week 48 , ass safety pharmacokinetic Japanese patient give entecavir dose 0.1 0.5 mg 52 week</brief_summary>
	<brief_title>A Study Japan Safety Antiviral Activity With Chronic Hepatitis B Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Documentation chronic hepatitis B infection ALL following : 1 . Positive HBsAg OR , negative IgM core antibody confirmation chronic hepatitis B liver biopsy 2 . Positive HBeAg OR negative HBeAg 3 . Documented HBV Viremia 2 occasion screen visit : Viremia sample drawn AND HBV DNA â‰¥ 10*5* copies/mL PCR assay screen visit ALT range 1.3 10 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>